Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sierra Oncology stock

Learn how to easily invest in Sierra Oncology stock.

Sierra Oncology Inc is a biotechnology business based in the US. Sierra Oncology shares (SRRA) are listed on the NASDAQ and all prices are listed in US Dollars. Sierra Oncology employs 109 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sierra Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SRRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Sierra Oncology stock price (NASDAQ: SRRA)

Use our graph to track the performance of SRRA stocks over time.

Sierra Oncology shares at a glance

Information last updated 2022-07-01.
Latest market close$54.99
52-week range$14.91 - $55.19
50-day moving average $54.73
200-day moving average $33.52
Wall St. target price$55.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-6.59

Buy Sierra Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sierra Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sierra Oncology price performance over time

Historical closes compared with the close of $54.99 from 2022-07-01

1 week (2022-06-24) 0.15%
1 month (2022-05-29) N/A
3 months (2022-03-31) 71.58%
6 months (2021-12-31) 152.94%
1 year (2021-07-02) 178.43%
2 years (2020-07-02) 360.17%
3 years (2019-07-02) 10,100.33%
5 years (2017-06-30) 4,600.00%

Sierra Oncology financials

Revenue TTM $200,000
Gross profit TTM $-59,953,000
Return on assets TTM -32.85%
Return on equity TTM -56.54%
Profit margin 0%
Book value $10.99
Market capitalisation $1.3 billion

TTM: trailing 12 months

Sierra Oncology share dividends

We're not expecting Sierra Oncology to pay a dividend over the next 12 months.

Have Sierra Oncology's shares ever split?

Sierra Oncology's shares were split on a 1:40 basis on 22 January 2020. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sierra Oncology shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Sierra Oncology shares which in turn could have impacted Sierra Oncology's share price.

Sierra Oncology share price volatility

Over the last 12 months, Sierra Oncology's shares have ranged in value from as little as $14.91 up to $55.19. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sierra Oncology's is 0.0154. This would suggest that Sierra Oncology's shares are less volatile than average (for this exchange).

Sierra Oncology overview

Sierra Oncology, Inc. , a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc.

Frequently asked questions

What percentage of Sierra Oncology is owned by insiders or institutions?
Currently 8.585% of Sierra Oncology shares are held by insiders and 85.088% by institutions.
How many people work for Sierra Oncology?
Latest data suggests 109 work at Sierra Oncology.
When does the fiscal year end for Sierra Oncology?
Sierra Oncology's fiscal year ends in December.
Where is Sierra Oncology based?
Sierra Oncology's address is: 1820 Gateway Drive, San Mateo, CA, United States, 94404
What is Sierra Oncology's ISIN number?
Sierra Oncology's international securities identification number is: US82640U4040
What is Sierra Oncology's CUSIP number?
Sierra Oncology's Committee on Uniform Securities Identification Procedures number is: 74346L101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site